134 related articles for article (PubMed ID: 12680143)
21. Extreme drug resistance assay results do not influence survival in women with epithelial ovarian cancer.
Karam AK; Chiang JW; Fung E; Nossov V; Karlan BY
Gynecol Oncol; 2009 Aug; 114(2):246-52. PubMed ID: 19500821
[TBL] [Abstract][Full Text] [Related]
22. Lack of effective systemic therapy for recurrent clear cell carcinoma of the ovary.
Crotzer DR; Sun CC; Coleman RL; Wolf JK; Levenback CF; Gershenson DM
Gynecol Oncol; 2007 May; 105(2):404-8. PubMed ID: 17292461
[TBL] [Abstract][Full Text] [Related]
23. Paclitaxel and cisplatin combination chemotherapy in recurrent epithelial ovarian cancer.
Goldberg JM; Piver MS; Hempling RE; Recio FO
Gynecol Oncol; 1996 Dec; 63(3):312-7. PubMed ID: 8946864
[TBL] [Abstract][Full Text] [Related]
24. Carboplatin-paclitaxel- and carboplatin-docetaxel-induced cytotoxic effect in epithelial ovarian carcinoma in vitro.
Engblom P; Rantanen V; Kulmala J; Grènman S
Cancer; 1999 Nov; 86(10):2066-73. PubMed ID: 10570433
[TBL] [Abstract][Full Text] [Related]
25. Apoptosis-based evaluation of chemosensitivity in ovarian cancer patients.
Flick MB; O'Malley D; Rutherford T; Rodov S; Kamsteeg M; Hao XY; Schwartz P; Kacinski BM; Mor G
J Soc Gynecol Investig; 2004 May; 11(4):252-9. PubMed ID: 15120700
[TBL] [Abstract][Full Text] [Related]
26. Extreme drug resistance is common after prior exposure to paclitaxel.
Geisler JP; Linnemeier GC; Thomas AJ; Manahan KJ
Gynecol Oncol; 2007 Sep; 106(3):538-40. PubMed ID: 17561236
[TBL] [Abstract][Full Text] [Related]
27. Docetaxel: an alternative taxane in ovarian cancer.
Katsumata N
Br J Cancer; 2003 Dec; 89 Suppl 3(Suppl 3):S9-S15. PubMed ID: 14661041
[TBL] [Abstract][Full Text] [Related]
28. Medical therapy of advanced malignant epithelial tumours of the ovary.
Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
[TBL] [Abstract][Full Text] [Related]
29. Navitoclax augments the activity of carboplatin and paclitaxel combinations in ovarian cancer cells.
Stamelos VA; Robinson E; Redman CW; Richardson A
Gynecol Oncol; 2013 Feb; 128(2):377-82. PubMed ID: 23168176
[TBL] [Abstract][Full Text] [Related]
30. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma.
Vasey PA; Jayson GC; Gordon A; Gabra H; Coleman R; Atkinson R; Parkin D; Paul J; Hay A; Kaye SB;
J Natl Cancer Inst; 2004 Nov; 96(22):1682-91. PubMed ID: 15547181
[TBL] [Abstract][Full Text] [Related]
31. The Bcl-2/Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin.
Witham J; Valenti MR; De-Haven-Brandon AK; Vidot S; Eccles SA; Kaye SB; Richardson A
Clin Cancer Res; 2007 Dec; 13(23):7191-8. PubMed ID: 18056200
[TBL] [Abstract][Full Text] [Related]
32. Improved survival trends in platinum-resistant patients with advanced ovarian, fallopian or peritoneal cancer treated with first-line paclitaxel/platinum chemotherapy: the impact of novel agents.
Bamias A; Bamia C; Zagouri F; Kostouros E; Kakoyianni K; Rodolakis A; Vlahos G; Haidopoulos D; Thomakos N; Antsaklis A; Dimopoulos MA
Oncology; 2013; 84(3):158-65. PubMed ID: 23296063
[TBL] [Abstract][Full Text] [Related]
33. Taxane sensitivity of ovarian carcinoma in vitro.
Engblom P; Rantanen V; Kulmala J; Heiskanen J; Grenman S
Anticancer Res; 1997; 17(4A):2475-9. PubMed ID: 9252666
[TBL] [Abstract][Full Text] [Related]
34. Paclitaxel (Taxol)/ifosfamide-based chemotherapy in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
Shin DM
Semin Oncol; 2000 Feb; 27(1 Suppl 1):36-40. PubMed ID: 10697043
[TBL] [Abstract][Full Text] [Related]
35. Heterogeneity of drug resistance in human breast and ovarian cancers.
Kern DH
Cancer J Sci Am; 1998; 4(1):41-5. PubMed ID: 9467045
[TBL] [Abstract][Full Text] [Related]
36. Cost-effectiveness of combination versus sequential docetaxel and carboplatin for the treatment of platinum-sensitive, recurrent ovarian cancer.
Havrilesky LJ; Pokrzywinski R; Revicki D; Higgins RV; Nycum LR; Kohler MF; Berchuck A; Myers ER; Secord AA
Cancer; 2012 Jan; 118(2):386-91. PubMed ID: 21598242
[TBL] [Abstract][Full Text] [Related]
37. [Clinical efficacy analysis of chemotherapy to lymph node metastasis in epithelial ovarian cancer].
Wu LY; Zhang R; Huang MN; Li N; Wang GX; Liu LY
Ai Zheng; 2003 Apr; 22(4):424-7. PubMed ID: 12704005
[TBL] [Abstract][Full Text] [Related]
38. The "Leuven" dose-dense paclitaxel/carboplatin regimen in patients with recurrent ovarian cancer.
Cadron I; Leunen K; Amant F; Van Gorp T; Neven P; Vergote I
Gynecol Oncol; 2007 Aug; 106(2):354-61. PubMed ID: 17499348
[TBL] [Abstract][Full Text] [Related]
39. Placental leucine aminopeptidase (P-LAP) expression is associated with chemosensitivity in human endometrial carcinoma.
Shibata K; Kikkawa F; Kondo C; Mizokami Y; Kajiyama H; Ino K; Nomura S; Mizutani S
Gynecol Oncol; 2004 Nov; 95(2):307-13. PubMed ID: 15491750
[TBL] [Abstract][Full Text] [Related]
40. Correlation between extreme drug resistance assay and response to primary paclitaxel and cisplatin in patients with epithelial ovarian cancer.
Eltabbakh GH; Piver MS; Hempling RE; Recio FO; Lele SB; Marchetti DL; Baker TR; Blumenson LE
Gynecol Oncol; 1998 Sep; 70(3):392-7. PubMed ID: 9790793
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]